Tags

Type your tag names separated by a space and hit enter

Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019.
J Infect Dis. 2020 06 29; 222(2):206-213.JI

Abstract

BACKGROUND

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), is associated with respiratory-related disease and death. Assays to detect virus-specific antibodies are important to understand the prevalence of infection and the course of the immune response.

METHODS

Quantitative measurements of plasma or serum antibodies to the nucleocapsid and spike proteins were analyzed using luciferase immunoprecipitation system assays in 100 cross-sectional or longitudinal samples from patients with SARS-CoV-2 infection. A subset of samples was tested both with and without heat inactivation.

RESULTS

At >14 days after symptom onset, antibodies against SARS-CoV-2 nucleocapsid protein showed 100% sensitivity and 100% specificity, whereas antibodies to spike protein were detected with 91% sensitivity and 100% specificity. Neither antibody levels nor the rate of seropositivity were significantly reduced by heat inactivation of samples. Analysis of daily samples from 6 patients with COVID-19 showed anti-nucleocapsid and spike protein antibodies appearing between days 8 and 14 after initial symptoms. Immunocompromised patients generally had a delayed antibody response to SARS-CoV-2, compared with immunocompetent patients.

CONCLUSIONS

Antibody to the nucleocapsid protein of SARS-CoV-2 is more sensitive than spike protein antibody for detecting early infection. Analyzing heat-inactivated samples with a luciferase immunoprecipitation system assay is a safe and sensitive method for detecting SARS-CoV-2 antibodies.

Authors+Show Affiliations

National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA.Division of Infectious Diseases and Travel Medicine, Evergreen Health, Kirkland, Washington, USA.Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA.Division of Infectious Diseases and Global Public Health, San Diego Center for AIDS Research, University of California San Diego, San Diego, California, USA.Division of Infectious Diseases and Global Public Health, San Diego Center for AIDS Research, University of California San Diego, San Diego, California, USA.Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Pub Type(s)

Journal Article
Research Support, N.I.H., Intramural

Language

eng

PubMed ID

32427334

Citation

Burbelo, Peter D., et al. "Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019." The Journal of Infectious Diseases, vol. 222, no. 2, 2020, pp. 206-213.
Burbelo PD, Riedo FX, Morishima C, et al. Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019. J Infect Dis. 2020;222(2):206-213.
Burbelo, P. D., Riedo, F. X., Morishima, C., Rawlings, S., Smith, D., Das, S., Strich, J. R., Chertow, D. S., Davey, R. T., & Cohen, J. I. (2020). Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019. The Journal of Infectious Diseases, 222(2), 206-213. https://doi.org/10.1093/infdis/jiaa273
Burbelo PD, et al. Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019. J Infect Dis. 2020 06 29;222(2):206-213. PubMed PMID: 32427334.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019. AU - Burbelo,Peter D, AU - Riedo,Francis X, AU - Morishima,Chihiro, AU - Rawlings,Stephen, AU - Smith,Davey, AU - Das,Sanchita, AU - Strich,Jeffrey R, AU - Chertow,Daniel S, AU - Davey,Richard T, AU - Cohen,Jeffrey I, PY - 2020/04/14/received PY - 2020/05/16/accepted PY - 2020/5/20/pubmed PY - 2020/7/8/medline PY - 2020/5/20/entrez KW - COVID-19 KW - SARS-CoV-2 KW - coronavirus KW - serology SP - 206 EP - 213 JF - The Journal of infectious diseases JO - J. Infect. Dis. VL - 222 IS - 2 N2 - BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), is associated with respiratory-related disease and death. Assays to detect virus-specific antibodies are important to understand the prevalence of infection and the course of the immune response. METHODS: Quantitative measurements of plasma or serum antibodies to the nucleocapsid and spike proteins were analyzed using luciferase immunoprecipitation system assays in 100 cross-sectional or longitudinal samples from patients with SARS-CoV-2 infection. A subset of samples was tested both with and without heat inactivation. RESULTS: At >14 days after symptom onset, antibodies against SARS-CoV-2 nucleocapsid protein showed 100% sensitivity and 100% specificity, whereas antibodies to spike protein were detected with 91% sensitivity and 100% specificity. Neither antibody levels nor the rate of seropositivity were significantly reduced by heat inactivation of samples. Analysis of daily samples from 6 patients with COVID-19 showed anti-nucleocapsid and spike protein antibodies appearing between days 8 and 14 after initial symptoms. Immunocompromised patients generally had a delayed antibody response to SARS-CoV-2, compared with immunocompetent patients. CONCLUSIONS: Antibody to the nucleocapsid protein of SARS-CoV-2 is more sensitive than spike protein antibody for detecting early infection. Analyzing heat-inactivated samples with a luciferase immunoprecipitation system assay is a safe and sensitive method for detecting SARS-CoV-2 antibodies. SN - 1537-6613 UR - https://www.unboundmedicine.com/medline/citation/32427334/Sensitivity_in_Detection_of_Antibodies_to_Nucleocapsid_and_Spike_Proteins_of_Severe_Acute_Respiratory_Syndrome_Coronavirus_2_in_Patients_With_Coronavirus_Disease_2019_ L2 - https://academic.oup.com/jid/article-lookup/doi/10.1093/infdis/jiaa273 DB - PRIME DP - Unbound Medicine ER -